Haisco Pharmaceutical Announces Public Offering for Clinical Studies
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) is set to make another public offering...
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...
Ji Xing Pharmaceuticals Acquires Global Rights to PhaseBio’s PB6440
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, has announced a deal to obtain global...
Mabwell’s Novel ADC 9MW2921 Accepted for NMPA Review
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing...
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
GSK Reports Strong Q4 and Full-Year 2022 Financials Amid Strategic Shift
UK-based GlaxoSmithKline plc (NYSE: GSK) has released its financial report for Q4 and the full-year...
China’s NMPA Releases 64th Batch of Reference Drugs for Generic Quality Consistency Evaluation
China’s National Medical Products Administration (NMPA) has released the 64th batch of reference drugs for...
Bristol-Myers Squibb’s Ozanimod Approved in China for Multiple Sclerosis
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced receiving marketing approval from China’s National Medical Products...
Roche Reports 2% YOY Growth in 2022; Ocrevus and Hemlibra Drive Sales
Swiss pharmaceutical giant Roche (SWX: RO) released its 2022 financial report this week, recording CHF...
Merck & Co. Posts 22% YOY Sales Growth; Keytruda and Gardasil Drive Revenues
Merck & Co. (NYSE: MRK) has released its Q4 and full-year 2022 financial report, showcasing...
Takeda Posts Strong Q3 Results, Announces Pipeline Advances in Oncology and Rare Diseases
Japan-based pharmaceutical giant Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...
GenScript’s CAR-T Therapy Carvykti Achieves $55M in Sales, Awaits China Approval
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that sales of...
Zhejiang Gongdong to Acquire Trademark Plastics for Overseas Expansion
China-based Zhejiang Gongdong Medical Technology Co., Ltd is set to acquire core assets of US...
Innovent Biologics Posts Strong Q4 Revenues Amid COVID-19 Challenges
Innovent Biologics Inc. (HKG: 1801) announced product revenues of RMB 1 billion (USD 148.2 million)...
Shanghai Weimu Medical Raises Pre-Series A+ Funding for Clinical Development
China-based high-end interventional device maker Shanghai Weimu Medical Technology Co., Ltd has reportedly raised “tens...
MicroPort Endovascular Plans RMB 2.55 Billion Private Placement
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) plans to raise up to RMB...
OcuMension’s Phase I Study for Dry Eye Treatment OT-202 Concludes
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the conclusion of a Phase I...
Eli Lilly Reports Q4 Financials with COVID-19 Impact and Market Performers
Eli Lilly & Co. (NYSE: LLY) reported its Q4 2022 financials, revealing a 9% year-on-year...
Virpax Pharmaceuticals Seeks China Licensing Partner for Non-Opioid Pain Drug Envelta
US-based Virpax Pharmaceuticals Inc. (NASDAQ: VRPX) has announced the engagement of advisors to help search...